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Pregnancy in a woman with prosthetic heart valve is
associated with difficult issues that include selection of the
appropriate prosthesis before gestation and the prevention
and treatment of potential complications to both the mother
and fetus during pregnancy, labor and delivery (1).
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The selection of a prosthetic heart valve for women of
childbearing age remains difficult (Table 1). New generation
mechanical valves offer excellent durability and low risk of
reoperation and superior hemodynamic profile. However,
their thrombogenicity and need for anticoagulation are
associated with an increased risk of thromboembolism,
maternal bleeding and fetal loss. The use of tissue valves is
also associated with major limitations. These valves have
high incidence of valve deterioration in young patients,
which is further accelerated during pregnancy (2–5) (Table
2), and may lead to valve re-replacement within 10 years in
approximately 30% of the patients. In general, heterograft
bioprostheses provide an inferior hemodynamic profile
when compared with new-generation mechanical valves,
especially the small sizes in the aortic position (6). Although
homograft valves and new pericardial valves seem to have
better hemodynamics than standard porcine valves, infor-
mation regarding pregnancy in women with these valves is
either not available or limited (7). Transplantation of the
patients’ own pulmonary valve to the aortic position and
implantation of a homograft in the pulmonary position
(Ross procedure) may be an attractive option for aortic valve
replacement in young women (8). More information, how-
ever, is needed regarding the long-term durability and effect
of pregnancy on the transplanted pulmonary valve. Because
of their durability, hemodynamic advantage, and relatively
small risk of thromboembolic and bleeding complications,
with careful anticoagulation, second generation mechanical
prostheses seem to be the preferred choice in all women who
need valve replacement during their childbearing age, and
are committed to a close follow up (1).
The risks associated with pregnancy in a woman with a
mechanical prosthetic valve are related mainly to the in-
creased hemodynamic burden due to physiological circula-
tory changes (5), increased incidence of thromboembolic
events due to pregnancy-related hypercoagulability and
maternal as well as fetal untoward effects caused by cardio-
vascular drugs and anticoagulation. Reported experience in
over 1,000 pregnancies in patients with one or more
prosthetic heart valves (1–5,9,10) indicates that most
asymptomatic or mildly symptomatic patients before gesta-
tion tolerate the hemodynamic burden of pregnancy, al-
though decreased functional capacity and need to start or
augment drug therapy are not uncommon.
Increased thromboembolic events have been clearly dem-
onstrated in patients with mechanical prosthetic valves
during gestation (Table 3). The reported incidence has been
as high as 10–15%, with approximately two-thirds of these
patients presenting with valve thrombosis leading to a 40%
mortality rate (2–4,9). Thromboembolism, however, has
been reported mostly in patients with older-generation
mechanical valves (Starr-Edwards, Bjork-Shiley, and so
forth) in the mitral position (2–4). The enhanced risk of
thromboembolism indicates the need for even more effective
anticoagulation during gestation. Heparin has been consid-
ered the anticoagulant of choice during pregnancy because
of its proved safety for both the patient and the fetus (11);
oral anticoagulant agents have been considered contraindi-
cated in pregnancy due to their teratogenic effect, increased
fetal bleeding complications and risk of central nervous
system damage during gestation (12). Recent publications,
however, reported an increased incidence of valve thrombo-
sis in patients with mechanical prosthesis treated with
subcutaneous heparin during pregnancy (3,4,9,13,14).
These findings, although limited by a retrospective nature of
the studies, small number of patients included and lack of
information regarding therapeutic level of anticoagulation,
led to recommendations by the European Society of Car-
diology (15), which have been recently included in the
American College of Cardiology/American Heart Associa-
tion guidelines (16), for the use of warfarin as an anticoag-
ulant of choice for the first 35 weeks of pregnancy in
patients with a mechanical prosthetic valve (3,9,15,16).
These recommendations have been problematic and have
not been adopted by both patients and physicians, especially
in the United States. Women in general are unwilling to
take warfarin during the first trimester of pregnancy (17).
The attitude of physicians is reflected by the fact that 96%
of 438 members of the Society of Perinatal Obstetricians
surveyed on their preferred management of a pregnant
patient with a mechanical prosthesis in the mitral position
selected discontinuation of warfarin and use of full-dose
heparin for the duration of pregnancy (18). This obvious
concern regarding use of warfarin during pregnancy is
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related to the risk of fetal effect especially warfarin-induced
embryopathy, which may be manifested by nasal deforma-
tion including depressed nasal bridge, nasal hypoplasia,
small nasal bones and hypoplastic alae nasi. In addition,
telecanthus, upper airway obstruction due to choanal steno-
sis, and punctate epiphyseal dysplasia of the long bones, the
cervical and lumbar vertebral plates may occur. The exact
incidence of warfarin-induced teratogenic effects is not
clear, and the majority of available studies indicate an
incidence of 5% to 10% (1). In this issue of the Journal of the
American College of Cardiology, Vitale et al. (19) make an
important contribution demonstrating a close dependency
between warfarin dosage and fetal complications. In this
report, 22 of 25 women (88%) whose warfarin dose was
.5 mg/day had fetal complications with a 9% incidence of
warfarin embryopathy. In contrast, only 5 of 33 cases (15%)
treated with a small dose warfarin (#5 mg/day) had fetal
complications and none of them had warfarin embryopathy.
These findings may suggest the feasibility of risk free use of
warfarin during pregnancy in patients with prosthetic heart
valves who can be well anticoagulated with #5 mg of
warfarin/day. At the same time, however, the results of this
report are limited by a small number of patients, lack of
control group and the mandatory cesarean section used by
the authors to prevent bleeding in the anticoagulated
neonate secondary to the trauma of vaginal delivery. This
approach may be associated with an increased risk of
maternal morbidity as well as prolongation of hospital stay.
Lack of a control group does not allow true analysis of the
risk associated with the use of a small dose of warfarin
during pregnancy.
Our recommendations for anticoagulation in pregnant
patients with mechanical valve prosthesis vary somewhat
from those offered by Vitale et al. (19), and are shown in
Figure 1. Our suggested treatment differentiates between
patients at lower and higher risk. Patients with first-
generation prosthetic valves in the mitral position should be
informed regarding the reported potential resistance to
moderate doses of heparin during pregnancy and offered the
option of warfarin therapy for the first 35 weeks, especially
those who can achieve therapeutic anticoagulation with
#5 mg/day of warfarin. Because of the remaining concern
regarding fetal effect of warfarin and the medico-legal
implications of its use during pregnancy, patients should
also be informed on the questionable nature of the evidence
supporting the gestational use of this drug (20). An alter-
native therapy for patients electing to avoid warfarin in the
first gestational trimester is intravenous or subcutaneous
heparin for the first trimester followed by warfarin between
13 and 36 weeks and then intravenous or subcutaneous
Table 2. Evidence for Tissue/Valve Deterioration During Pregnancy
Reference
Number of
Pregnancies
Number of Patients
With Valve
Deterioration Comments
Born et al. (2) 25 4 (16%) 2 maternal deaths
Sbarouni and Oakley (3) 49 17 (35%) 2 operated during pregnancy and
15 shortly thereafter
Hanania et al. (4) 74 7 (10%)
Lee et al. (5) 95 4 (4%) 10-year valve survival
1 pregnancy, 55%
– – 2 pregnancies, 17%
243 32 (13%)
Modified, with permission, from Elkayam and Khan (1).
Table 1. Comparison of Advantages and Disadvantages of Tissue and Mechanical Valves
in Pregnancy
Property/Outcome Tissue Mechanical
Durability Limited (10 to 12 years) Indefinite
Thromboembolism Low risk High risk if not anticoagulated
Anticoagulation Not needed after initial 3
months
Required indefinitely
Hemodynamics Good, with exception of smallest
valve sizes
Excellent
Accelerated deterioration
during pregnancy
Yes No
Fetal loss No effect Increased
Prematurity Probably no effect Increased
Small-for-date Probably no effect Increased
Reproduced, with permission, from Elkayam and Khan (1).
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heparin until delivery. High heparin intensity should be
used in patients at high risk. We now follow antifactor Xa
levels in all our pregnant patients treated with heparin
aiming at an intensity of 0.55–0.8 U/ml. Previously, a
mid-interval APTT ratio of 1.5 was considered by some
investigators to be therapeutic in patients with prosthetic
valves treated with heparin (3,9). Measuring antifactor Xa
levels along with the APTT, McGehee found an APTT
ratio of 1.5 not to achieve even a low therapeutic intensity in
50% of patients (11). In contrast, a APTT ratio of $2.0
correlated with a high intensity heparin concentration
(.0.55 Xa inhibition unit) in 90% of patient samples. These
findings are in agreement with recent recommendations to
use a target APTT ratio of $2.0 in patients with prosthetic
valves treated with heparin during pregnancy (20). Because
commercial APTT reagents vary in their responsiveness to
heparin, it has been recommended that laboratories calibrate
their APTT therapeutic range to be equivalent to a heparin
level of 0.2–0.4 U/ml by protamine titration or an antifactor
Xa level of 0.3–0.7 U/ml (12). In addition, because of
potential disparity between heparin concentration and the
APTT in the third trimester (21), the use of anti-Xa assays
may be more useful for guidance of heparin therapy during
this phase of pregnancy.
Two of the cases reported by Vitale et al. (19) with
older-generation mechanical prostheses in the mitral posi-
tion and an INR ,3.0 developed valve thrombosis that led
to urgent surgery in both and to fetal loss in one of them.
These cases emphasize the need to use high enough doses of
warfarin to maintain an INR level between 3.0 and 4.5 in
high risk patients (22). Because of high incidence of
premature labor in patients with prosthetic heart valves
(9,17), warfarin should be substituted with heparin at 35 or
36 gestational week to avoid onset of labor during warfarin
therapy. To assure adequacy of anticoagulation, the switch
from coumadin to heparin should be performed in the
hospital. In patients with lower risk for thromboembolic
events, including those with aortic prosthetic valve and
second generation prosthesis in the mitral position, we
advocate an adjusted dose of subcutaneous heparin therapy
throughout pregnancy (APTT 2.0–3.0). In the last several
years we have used this approach in approximately 15
patients with St. Judes valves in the aortic, mitral or both
positions without a single episode of thromboembolic event.
The use of warfarin during weeks 13 to 35 or 36 is an
alternative regimen in cases where self-injection of heparin
is not desirable by the patient or is associated with side
effects. Higher level of anticoagulation seems justified in
patients with mechanical prostheses in the mitral position,
in patients with more than one mechanical prosthesis and in
patients with atrial fibrillation and history of systemic
embolization. The intensity of anticoagulation should be
frequently monitored and immediately corrected if needed.
Because a small-dose aspirin is safe during pregnancy (20)
and has been shown to reduce the incidence of systemic
embolization or death when added to oral anticoagulation in
the non-pregnant population with mechanical prosthetic
valves (23), 80 mg of aspirin may be added to maximize
antithrombotic effects.
There is a great deal of interest in the use of low
molecular weight heparin (LMWH) as a substitute for
unfractionated heparin in patients with prosthetic heart
valves during pregnancy. The data to support the use of
LMWH, however, is not yet available. We have recently
used LMWH without complications in two pregnant
women with St. Jude’s valve in the mitral position in the first
and in the aortic position in the second. A similar successful
use of LMWH was reported during pregnancy in two
Chinese women with Starr Edwards mitral valves (24). The
LMWH may provide better effect because of superior
bioavailability and may reduce risk of bleeding and osteo-
porosis. This drug, however, is less readily reversible by
protamine sulfate, has a long half life and may be more
Table 3. Incidence of Major Thromboembolic Events During Pregnancy
Reference
Major TE
Events
Valve
Thrombosis Death Pregnancies Patients
Born et al. (2) 4 (10%) 3 0 40 NA
Sbarouni and Oakley (3) 21 (14%) 13 6 151 133
Hanania et al. (4) 22 (23%) 10 3 95 NA
Salazar et al. (9) 3 (7.5%) 2 2 40 37
Reproduced, with permission, from Elkayam and Khan (1).
NA 5 not available; TE 5 thromboembolic events.
Figure 1. Recommendations for anticoagulation in women with
mechanical prosthetic heart valve during pregnancy.
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difficult to handle during labor and delivery. More informa-
tion is therefore required before LMWH can be recom-
mended for anticoagulation in a patient with a prosthetic
valve during gestation.
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